

Special Issue

Multimodality and Sequential Therapy in Locally Advanced Head and Neck Cancer

Message from the Guest Editors

The treatment of locally advanced head and neck cancer is often challenging. Despite the surgical and nonsurgical innovations in the last few decades, the oncologic and functional outcomes are not always improved. Multimodality and sequential therapy arose for locally advanced cancers and included induction chemotherapy, chemoradiation with organ-preservation protocols, immunotherapy, and targeted therapy. Surgery remains an important option, including after chemoradiotherapy failure. Moreover, treatment-related toxicity negatively affects patients' quality of life and should be taken into account during treatment choice. This Special Issue aims to highlight the current state of the art and to describe future perspectives for the multimodal management of locally advanced head and neck cancer. In particular, original research articles and reviews on sequential treatment, but also on the role of surgery after induction chemotherapy or as a salvage approach, are welcome.

Guest Editors

Prof. Dr. Giancarlo Pecorari

Division of Otorhinolaryngology, Department of Surgical Sciences, University of Turin, 10126 Torino, Italy

Dr. Giuseppe Riva

Department of Surgical Sciences, University of Turin, 10126 Torino, Italy

Deadline for manuscript submissions

closed (30 April 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/79422

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)